公开(公告)号：US20210230115A1

公开(公告)日：2021-07-29

申请号：US17055506

申请日：2019-05-16

Applicant: INFEX Therapeutics Limited

Inventor： Ian Cooper ,  David ORR ,  Andrew Wilkinson ,  Jonathan Finlayson ,  Adam Bunt ,  Pia Appelqvist ,  Hans Wallberg ,  Fredrik Wångsell

IPC: C07D207/48 ,  C07D403/04 ,  C07D401/04 ,  C07D401/10 ,  C07D403/14 ,  C07D207/36 ,  C07D401/14 ,  C07D487/04 ,  C07D417/04 ,  C07D403/12 ,  A61P31/04

Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

公开(公告)号：US20230286915A1

公开(公告)日：2023-09-14

申请号：US18246777

申请日：2021-10-06

Applicant: INFEX Therapeutics Limited

Inventor： Andrew Wilkinson ,  lan Cooper ,  David Orr ,  Jonathan Finlayson ,  Adam Bunt ,  James Kirkham ,  David Lyth ,  Kevin Blades

IPC: C07D207/48

CPC classification number: C07D207/48

Abstract: This invention relates to the synthesis of compounds that can be used to treat bacterial infections in combination with other antibacterial agents, and more specifically in combination with a class of antibacterial agents known as carbapenems. The compounds resulting from the novel methods of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

公开(公告)号：US11459296B2

公开(公告)日：2022-10-04

申请号：US17055506

申请日：2019-05-16

Applicant: INFEX Therapeutics Limited

Inventor： Ian Cooper ,  David Orr ,  Andrew Wilkinson ,  Jonathan Finlayson ,  Adam Bunt ,  Pia Appelqvist ,  Hans Wallberg ,  Fredrik Wångsell

IPC: C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D207/48 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D487/04 ,  C07D417/04 ,  A61P31/04 ,  C07D207/36

Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

公开(公告)号：US20240383852A1

公开(公告)日：2024-11-21

申请号：US18281038

申请日：2022-03-11

Applicant: INFEX Therapeutics Limited

Inventor： James Kirkham ,  Ian Cooper ,  Adam Bunt ,  Kevin Blades ,  David Orr ,  Andrew Wilkinson ,  Paul Schofield

IPC: C07D211/14 ,  A61K31/36 ,  A61K31/397 ,  A61K31/407 ,  A61K31/415 ,  A61K31/4375 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/451 ,  A61K31/495 ,  A61K31/4995 ,  A61K31/505 ,  A61K31/506 ,  A61K31/551 ,  C07D211/12 ,  C07D213/02 ,  C07D213/38 ,  C07D213/56 ,  C07D231/12 ,  C07D239/42 ,  C07D243/08 ,  C07D285/08 ,  C07D295/033 ,  C07D317/50 ,  C07D333/20 ,  C07D403/04 ,  C07D471/18 ,  C07D487/04 ,  C07D487/10

Abstract: This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.

公开(公告)号：US11845725B2

公开(公告)日：2023-12-19

申请号：US17946587

申请日：2022-09-16

Applicant: INFEX Therapeutics Limited

Inventor： Ian Cooper ,  David Orr ,  Andrew Wilkinson ,  Jonathan Finlayson ,  Adam Bunt ,  Pia Appelqvist ,  Hans Wallberg ,  Fredrik Wångsell

IPC: C07D207/48 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D403/12 ,  A61P31/04 ,  C07D207/36 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D417/04 ,  C07D487/04

CPC classification number: C07D207/48 ,  A61P31/04 ,  C07D207/36 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D417/04 ,  C07D487/04

Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

公开(公告)号：US20230060011A1

公开(公告)日：2023-02-23

申请号：US17946587

申请日：2022-09-16

Applicant: INFEX Therapeutics Limited

Inventor： Ian Cooper ,  David Orr ,  Andrew Wilkinson ,  Jonathan Finlayson ,  Adam Bunt ,  Pia Appelqvist ,  Hans Wallberg ,  Fredrik Wångsell

IPC: C07D207/48 ,  A61P31/04 ,  C07D207/36 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D417/04 ,  C07D487/04 ,  C07D401/12

Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

公开(公告)号：US20230018460A1

公开(公告)日：2023-01-19

申请号：US17778261

申请日：2020-11-19

Applicant: INFEX THerapeutics Limited

Inventor： Andrew Wilkinson ,  Ian Cooper ,  David Orr ,  Jonathan Finlayson ,  Adam Bunt ,  Pia Appelqvist ,  Hans Wallberg ,  Fredrik Wångsell ,  James Kirkham

IPC: A61K31/40 ,  A61K31/407 ,  A61K31/431 ,  A61K31/4162 ,  A61K31/427 ,  C07D207/48 ,  C07D401/12 ,  C07D403/12 ,  C07D487/10 ,  C07D401/04 ,  C07D403/04 ,  C07D401/06 ,  C07D401/14 ,  C07D471/08 ,  A61P31/04 ,  A61K31/454 ,  A61K31/4025 ,  A61K31/5377 ,  A61K31/4178 ,  A61K31/541 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/438 ,  A61K31/403

Abstract: This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections. More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.